 |
|
|
|
|
Product Details:
Payment & Shipping Terms:
|
| Name: | Semaglutide | Other Name: | Sermaglutide |
|---|---|---|---|
| Grade: | Pharma Grade | Molecular Formula: | C187H291N45O59 |
| Delivery: | 100% | MOQ: | 1 Kit |
| Specification: | 2mg, 5mg, 10mg Per Vial | Package: | 10 Vials Per Kit |
Wholesale Price Semaglutide Peptide 2mg 5mg 10mg Vials Semaglutide Injection
Product description:
In June 2008, a phase II clinical trial began studying semaglutide.
In 2012, a team of researchers at Novo Nordisk developed semaglutide for a once-weekly diabetes therapy as a longer-acting alternative to liraglutide. It was given the brand name Ozempic. Clinical trials started in January 2016 and ended in May 2017.
In March 2021, in a phase III randomized, double-blind, trial, 1,961 adults with a body mass index of 30 or greater were assigned in a 2:1 ratio to a treatment with once-weekly subcutaneous semaglutide or placebo, plus lifestyle intervention. The trials occurred at 129 sites in 16 countries in Asia, Europe, North America, and South America. The mean percentage change in body weight at week 68 was −14.9% in the semaglutide group vs −2.4% with placebo, for an estimated treatment difference of −12.4 percentage points (95% CI, −13.4 to −11.5).
A 2022 review of anti-obesity treatments found that semaglutide as well as tirzepatide (which has an overlapping mechanism of action) were more promising than previous anti-obesity drugs, although less effective than bariatric surgery.
The US Food and Drug Administration (FDA) approved semaglutide based on evidence from seven clinical trials of 4087 participants with type 2 diabetes. The trials were conducted at 536 sites in 33 countries, including Canada, Mexico, Russian Federation, Ukraine, Turkey, India, South Africa, Japan, Hong Kong, multiple European countries, Argentina, and the United States. In two of these trials (NCT #02054897 and NCT#02305381), participants were randomly assigned to receive either semaglutide or placebo injection weekly. Neither the participant nor the health care provider knew which treatment was being given until after the trials were completed. Treatment was given for 30 weeks. In the other five trials (NCT #01930188, 01885208, 02128932, 02207374, 02254291), participants were randomly assigned to receive either semaglutide or another antidiabetic medication, and the participant and provider knew which medication was being given in four trials. Treatment was given for 30 weeks or 56 weeks.
Related products:
| GH 10iu 191AA | GH Fragment 176-191 | Adipotide |
| Kigtropin | Tirzepatide | Epithalon |
| Getropin | Jintrop | Oxytocin 2 |
| Hygetrop | PT-141 | |
| HCG 5000iu Livzlon brand | Taitropin | GHK-CU |
| HCG 5000iu | BPC-157 | Fox04 dri |
| TB-500 | CJC-1295 | DSIP |
| Hexarelin | HMG 75iu | AOD9604 |
| Ipamorelin | Sermorelin | MGF |
| Selank | Semaglutide | Peg-mgf |
| Semax | Tesamorelin | EPO 3000iu |
| Thymalin | Thymosin alpha | Follistatin 344 |
| GHRP2 | GHRP6 | Kisspeptin-10 Peptide |
| Gondorelin | IGF-1 DES | Dermorphin |
| IGF-LR3 | Melanotan | ACE-031 |
| Mots-C | Myostatin | AICAR |
| Please contact us for more products | ||
Product Photos:
Certifications:
Company:
FAQ:
Contact Person: jason
Tel: +86 17792557883
